[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2015-2019 Life Science Intermediates Market Consolidation: Who will not survive?

July 2015 | 35 pages | ID: 205458AAEEAEN
Venture Planning Group

US$ 1,960.00 US$ 2,450.00 -20 %

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Will the industry consolidate, decentralize, or undergo a bimodal transformation?

How will the current trends affect the major market segments?

Which companies will enter the market and which will not survive? This new report from VPGMarketResearch.com provides technological know-how of leading life science intermediates companies. The report presents:
  • Internally developed and acquired technologies, and related capabilities.
  • Proprietary technologies and patent litigations.
The companies analyzed in the report: BASF, Bayer/Lanxess, Cambrex, Clariant, DowPharma, DSM, Evonik, Lonza, Novasep, and Rhodia.

Contains 35 pages
1. BASF

2. CAMBREX

3. CLARIANT

4. DOWPHARMA

5. DSM

6. EVONIK

7. LANXESS

8. LONZA

9. NOVASEP

10. RHODIA

FOR EACH COMPANY, THE REPORT PRESENTS:

Internally developed and acquired technologies, and related capabilities.
Proprietary technologies and patent litigations.


More Publications